Testing different ways to give bimekizumab for psoriatic arthritis or axial spondyloarthritis
Part of Bones, joints & muscles, Skin clinical trials.
This study looks at whether giving bimekizumab in different ways is safe and how it moves through the body over time. It is for adults with active psoriatic arthritis or axial spondyloarthritis who may benefit from bimekizumab treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have active psoriatic arthritis or axial spondyloarthritis that is suitable for bimekizumab treatment.
- Your weight is between 45 and 100 kg (if female) or 50 and 100 kg (if male).
- You have either never taken a biologic drug for your condition, or you stopped taking one at least 3 months or 5 half-lives ago.
- You do not have serious organ problems (like heart, liver, kidney), severe mental health issues, or recent infections (including tuberculosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
This study tests different targeted treatments for adults with rheumatoid arthritis who have already tried other biologic or targeted medications and need a new option. It aims to find which treatment works best for people like you.
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
This trial tests whether bimekizumab is better than adalimumab at reducing chest wall pain in people with active axial spondyloarthritis who haven't responded to NSAIDs. It aims to find a more effective treatment option for this specific symptom.
This trial tests if the drug bimekizumab can slow down chronic inflammation in people with early plaque psoriasis. It's for adults 18-44 with mild psoriasis who haven't used topical treatments recently.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.